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High glucoseα-Lipoic acid (LA) has been shown to improve the diabetic cardiac symptoms. However, the underlying
mechanisms have not been elucidated precisely. We have reported recently that LA potentially protected
neurons from substance-induced apoptosis. We hypothesized that LA could attenuate cardiac cells death in-
duced by oxidative stress derived from high glucose. To test this possibility, we examined the effects of LA on
D-glucose/glucose oxidase (DG/GO, 30 mM/5 mU)-induced injury in rat cardiomyoblast H9c2 cells. We
observed that LA pretreatment signiﬁcantly increased cell viability in DG/GO-challenged cells. LA pretreat-
ment also attenuated DG/GO-induced apoptosis as evidenced by decreases in both nuclear condensation
and loss of mitochondrial potential. In addition, LA activated ERK1/2 and moderately increased ROS produc-
tion. Blockade of ERK1/2 activation by PD98059 completely abolished LA-induced protection against DG/GO
challenge. Inhibition of ROS by N-acetylcysteine abrogated LA-induced ERK1/2 activation and cytoprotection.
Furthermore, we observed that the ROS production induced by LA was signiﬁcantly slower and milder
than that by DG/GO. Our results suggest that pretreatment with LA moderately increased ROS production
to induce a preconditioning-like effect by ERK1/2 activation thereby increased tolerance of H9c2 cells to
DG/GO challenge.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Diabetic cardiomyopathy is a distinct primary disease process,
which develops secondary to hyperglycemia. The mechanism by
which hyperglycemia causes damage of myocardium has not been
fully understood; however, cardiac apoptosis has been shown to be a
major early cellular response to diabetes [1,2]. Evidence indicates that
cardiac apoptosis induced by hyperglycemia is an important determi-
nant of cardiac remodeling because it causes a loss of contractile units,
compensatory hypertrophy of myocardial cells, and reparative ﬁbrosis
[3]. This increased cardiac apoptosis is associated with oxidative stress
induced by reactive oxygen species (ROS) derived from hyperglycemia
[3]. Hence, prevention of oxidative stress-induced cardiac apoptosis, First Afﬁliated Hospital with
jing 210029, China. Tel.: +86
l rights reserved.could be a strategy for targeting the pathogenesis of hyperglycemia-
induced myocardial damage [1–3].
α-Lipoic acid (LA) is a naturally occurring dithiol compound synthe-
sized enzymatically in the mitochondrion from octanoic acid. Although
LA has long been viewed as antioxidant, it is now evident that LA can
also transiently and moderately increase ROS production, which serves
as a signaling molecule [4–7]. We and others have demonstrated that
the moderately increased ROS content was positively correlated with
improvement of cell survival under stress [5,8,9]. Of particular impor-
tance to this study, LA has been used to treat various diabetic complica-
tions including neuropathy [10], retinopathy [11], nephropathy [12]
and endothelial dysfunction [13]. Very recently, LA has shown its pro-
tective effects on the development of diabetic cardiomyopathy in both
clinical patients and experimental rodents [14–16]. However, the
mechanisms bywhich LA protects hearts fromhyperglycemic challenge
have not been fully understood.
We reported recently that LA protected neurons from local
anesthetics-induced apoptosis [5]. We hypothesized that LA could
attenuate cardiac cell death induced by oxidative stress that derived
from high glucose. To test this possibility, we examined the effects
of LA on D-glucose (DG)/glucose oxidase (GO)-induced injury in rat
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effectively protected H9c2 cells from DG/GO-induced death. This
action of LA was mediated via moderately ROS induction to induce a
preconditioning-like effect by ERK1/2 activation.
2. Materials and methods
2.1. Chemicals and antibodies
LA, PD98059, DG, GO, 2′,7′-dichloroﬂuorescein diacetate (DCFH-DA),
dihydroethidium (DHE) and N-acetylcysteine (NAC) were purchased
from Sigma-Aldrich (St. Louis, MO). Hoechst 33342 reagent, Mito-
Tracker® Red CMXRos, Dulbecco's modiﬁed Eagle medium (DMEM)
and fetal calf serum (FCS) were obtained from Invitrogen (Carlsbad,
CA). 5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocya-
nine iodide (JC-1) was obtained from Biovision, Inc. (Mountain View,
CA). Primary antibodies for total-ERK1/2 (#9012) and phosphor-ERK1/
2 (p-ERK1/2, #9101) were obtained from Cell Signaling Technology
(Beverly, MA).MTT [3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyltetrazo-
lium bromide] reagent was from Bio Besic, Inc. (Markham, Ontario,
Canada). Protease inhibitor cocktail was from Roche (Mannheim,
Germany). BCA protein assay kit and supersignal west pico chemilumi-
nescent substrate were obtained from Pierce (Rockford, IL). H2O2 assay
kit was purchased from Jiancheng Biotech (Nanjing, China).
2.2. Tissue culture and experimental design
Rat cardiomyoblast H9c2 cells were obtained from ATCC and main-
tained in DMEM supplemented with 10% FCS. Cells were assigned to
four groups: (1) untreated control group (Con); (2) LA group: cells
were treated with LA (300 μM) for indicated times; (3) DG/GO group:
cells were stimulated with DG (30 mM) and GO (5 mU/ml) for indicat-
ed times as described previously [17,18]; (4) LA+DG/GO group: cells
were pretreated with LA (300 μM) for 12 h and followed by stimulation
withDG (30 mM) andGO (5 mU/ml) for indicated times. For examining
the effects of LA or PD98059 on cell proliferation, H9c2 cells were trea-
ted LA (0, 300, 500, 1000, 1500 and 2000 μM) or PD98059 (0, 10, 20, 30
and 40 μM) for 24 h. For ERK1/2 inhibition experiments, cells were
pretreated with PD98059 (30 μM) 30 min prior to LA administration.
For ROS inhibition experiments, cells were pretreated with NAC
(1.5 μM) 30 min prior to LA administration. For examining the effects
of NAC on DG/GO-induced cell injury, H9c2 cells were pretreated
with NAC (1.5, 5 and 10 μM) 30 min prior to DG/GO stimulation. For
examining the dose–response of H2O2 on cell viability, H9c2 cells
were treated with H2O2 for 24 h at concentrations of 0, 5, 50, 100, 125
and 300 μM.
2.3. Examination of cell viability and morphological changes
After treatment, cell viability was determined by MTT assay as
described previously [4]. In another set of experiments, cell morphol-
ogy was examined using phase-contrast light microscopy with a
magniﬁcation of 200× (Zeiss Ltd., Germany).
2.4. Examination of nuclear condensation
Nuclear condensation was examined by Hoechst 33342 staining.
After stimulation with DG/GO for 24 h, cells were ﬁxed with methanol/
acetone (50%:50%) for 10 min and incubated with Hoechst 33342
(0.4 μg/ml) for 5 min at room temperature. The stained nuclei were
then examined using a ﬂuorescence microscope with a magniﬁcation
of 200× (Zeiss Ltd., Germany). Four ﬁelds in each well were randomly
examined. The nuclear condensation was expressed as a percentage of
condensed nuclei to total nuclei.2.5. Measurement of intracellular ROS content and localization
Intracellular ROS content was measured by DCFH-DA assay as de-
scribed in our previous studies [4,5]. After treatment with LA or DG/
GO for the indicated times, DCFH-DA (10 μM)was introduced to culture
for 30 min. Datawere then collected by a ﬂuorometer (BIO-TEK, USA) at
an excitation/emission wavelength of 485/530 nm. In another set of
experiment, cells were co-stained DCFH-DA with MitoTracker® Red
CMXRos (100 nm), which was used to visualize mitochondria. After
30 min of staining, imageswere observed and captured using a confocal
microscope (Zeiss Ltd., Germany).
Superoxide anion (O2•−) was detected by DHE staining as previously
described method [19–21]. After treatment with LA or DG/GO for 1 h,
cells were stainedwith DHE (10 μM) for 30 min. Themeanﬂuorescence
units was measured by a ﬂuorometer (BIO-TEK, USA) at an excitation/
emission wavelength of 510/600 nm. The staining was also imaged
using a ﬂuorescence microscope with a magniﬁcation of 200× (Zeiss
Ltd., Germany).
2.6. Evaluation of mitochondrial transmembrane potential (ΔΨm)
We used JC-1 to evaluate ΔΨm. JC-1 dye exhibits a ΔΨm-dependent
accumulation in mitochondria and aggregates at high ΔΨm from a
green ﬂuorescent monomeric form to a red ﬂuorescence “J-aggregates”
[22,23]. The monomeric JC-1 and “J-aggregates” could be detected at
excitation wavelength/emission wavelength of 485 nm/528 nm and
530 nm/590 nm, respectively [22,23]. In our measurement system, JC-
1 (10 μg/ml) was added to the culture for 15 min in the dark after
the cells were treated with DG/GO for 12 and 24 h, respectively. After
washing thoroughly with PBS, the ﬂuorescence intensity was detected
and quantiﬁed using a ﬂuorometer (Synergy HT, BIO-TEK, USA) at exci-
tationwavelength/emissionwavelengths as described above.ΔΨmwas
expressed as the ratio of OD530nm/590 nm over OD485nm/528 nm.
After the ﬂuorescence quantiﬁcation, the images were also captured
using ﬂuorescence microscope (Zeiss Ltd., Germany).
2.7. Western blot analysis
Western blot was performed as described previously [5,17]. Brieﬂy,
the cytosolic fractions were extracted from H9c2 cells after treatment
with LA for 3 h. Equal amount of protein extracts were separated
on 10% SDS-PAGE gel and transferred onto immobilon-p membrane
(Milipore Corp., Bedford, MA). After blocking, the membrane was incu-
bated with primary antibody at 4 °C overnight and followed by incuba-
tion with an appropriate secondary antibody. The samemembrane was
also probed with anti-α-tubulin for loading control. The blots were
detected with ECL kit and the signals were quantiﬁed by scanning
densitometry.
2.8. Statistical analysis
Results are expressed as mean±standard deviation (x±SD).
Comparison of data between groups was performed using one-way
analysis of variance (ANOVA). Tukey's procedure for multiple range
tests was performed. Pb0.05 was considered to be signiﬁcant.
3. Results
3.1. LA pretreatment improves cell survival in DG/GO-treated cells
We ﬁrst examined the effects of LA on the proliferation in H9c2
cells. Fig. 1A shows that, compared with untreated controls, 300 μM
of LA did not cause signiﬁcant changes in cell proliferation. However,
cell proliferation was signiﬁcantly increased in 500 μM of LA group,
peaked in 1000 μM of LA group and then gradually decreased in
1500 μM of LA group, when compared with untreated controls.
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Fig. 1. LA increased viability in DG/GO-treated H9c2 cells. (A) Effects of LA on cell proliferation. H9c2 cells were treated with LA at indicated concentrations for 24 h. Cell viability
was detected by MTT assay. *Pb0.01 vs. 0 μM of LA group, n=5 per group. (B) LA increased viability in DG/GO-treated cells. H9c2 cells were treated with LA 12 h prior to stimu-
lation with DG/GO. Twenty-four hours after DG/GO stimulation, cell viability was detected by MTT assay. *Pb0.01, n=5 per group.(C) LA attenuated DG/GO-induced morphological
abnormalities. H9c2 cells were treated with LA 12 h prior to stimulation with DG/GO. Twenty-four hours after DG/GO stimulation, cellular morphology was observed using phase-
contrast microscope with a magniﬁcation of 200×. n=6 per group.
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did not show signiﬁcant difference with controls. Therefore, 300 μM
of LA was selected in the following experiments.
We next evaluated whether LA pretreatment could improve cell
survival in DG/GO-treated cells. As shown in Fig. 1B, DG/GO challenge
signiﬁcantly decreased cell viability by 59.5% (Pb0.01) compared with
untreated control. However, LA pretreatment signiﬁcantly attenuated
DG/GO-induced decrease of viability by 94.0% (Pb0.01) compared
with DG/GO-treated cells. LA administration alone did not signiﬁcantly
change cell viability.
Fig. 1C shows that LA pretreatment markedly improved cell mor-
phology followingDG/GO challenge. DG/GO challenge caused obviously
morphological changes, including applanate and shrunken shapes with
loss of cellular integrity when compared with untreated control.
However, LA pretreatment pronouncedly attenuated DG/GO-induced
morphological abnormalities. LA administration alone did not induce
cell morphological changes.3.2. LA pretreatment prevents DG/GO-induced apoptosis
Nuclear condensation is a typical marker for apoptotic cells [24].
As shown in Fig. 2A, DG/GO challenge signiﬁcantly increased
condensed nuclei by 6964.9% (Pb0.01) compared with untreated
However, LA pretreatment signiﬁcantly prevented DG/GO-induced
nuclear condensation by 92.3% (Pb0.01) compared with DG/GO-
treated group. LA administration alone did not induce nuclear
condensation.
The loss of mitochondrial membrane potential (ΔΨm) is a critical
step for activation of mitochondria-associated apoptotic signaling
pathway [22,23]. As shown in Fig. 2B, DG/GO challenge resulted in a
signiﬁcant loss of ΔΨm by 25.3% (12 h) and 41.6% (24 h), respectively,
compared with time-matched untreated controls. In LA-pretreated
cells, however, the DG/GO-induced loss ofΔΨmwas signiﬁcantly atten-
uated. LA pretreatment increased the levels ofΔΨm by 42.0% (12 h) and55.8% (24 h), respectively, comparedwith time-matched DG/GO group.
The right panel of Fig. 2B shows the representative images of JC-1
ﬂuorescence shift at 24 h after DG/GO stimulation.
3.3. LA-induced cytoprotection is mediated through ERK1/2 activation
Fig. 3A shows that the levels of p-ERK1/2was signiﬁcantly increased
in both DG/GO- and LA-treated cells, when compared with untreated
controls (Pb0.01). However, the level of p-ERK1/2 was signiﬁcantly
higher by 37.9% in LA group than that in DG/GO group (Pb0.01).
We then examined whether inhibition of ERK1/2 activation by
PD98059, a selective inhibitor for MEK/ERK1/2, will affect the cyto-
protection of LA from DG/GO challenge. Fig. 3B shows that treatment
with PD98059 at concentrations of 10,20, 30 and 40 μMdid not signif-
icantly change cell viability. Thus 30 μM of PD98059 was selected in
the following experiments. As shown in Fig. 3C, LA-induced ERK1/2
phosphorylation was blocked by PD98059. More importantly, blockade
of ERK1/2 phosphorylation by PD98059 completely abolished LA-
induced protection against DG/GO-induced both decrease of cell
survival (Fig. 3D) and increase of apoptosis (Fig. 3E). PD98059 treat-
ment alone had no signiﬁcantly effects on cell death. The data suggest
that LA-induced protection against DG/GO challenge was mediated
through activation of ERK1/2.
3.4. ERK1/2 activation by LA is ROS dependent
To investigate how LA activated ERK1/2, we examined whether LA
will induce ROS production because ROS has been considered as a
second messenger for ERK1/2 activation [4,25]. Fig. 4A shows that
LA increased ROS content in a time-dependent manner. Treatment
with LA for 0.5 h did not signiﬁcantly increase ROS level compared
with untreated control (0 h). However, ROS levels in LA-treated cells
were signiﬁcantly increased by 16.1% (1 h), 17.1% (6 h), 21.3% (12 h)
and 22.2% (24 h), respectively, compared with untreated control
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Fig. 2. LA prevented DG/GO-induced apoptosis.(A) LA prevented DG/GO-induced nuclear condensation. H9c2 cells were treated with LA 12 h prior to stimulation with DG/GO.
Twenty-four hours after DG/GO stimulation, nuclear condensation was examined by Hoechst 33342 staining. The right panel represents the images of nuclei that captured by
a ﬂuorescence microscope at a magniﬁcation of 200×. Arrows indicate the condensed nuclei, which is shown in bright blue. *Pb0.01, n=6–8 per group.(B) LA prevented DG/
GO-induced loss of mitochondrial potential (ΔΨm). H9c2 cells were treated with LA 12 h prior to stimulation with DG/GO. ΔΨm was determined by JC-1 staining at 12 and 24 h
after DG/GO stimulation. The right panel shows the representative images of JC-1 ﬂuorescence shift at 24 h after DG/GO stimulation (magniﬁcation: 200×). Red ﬂuorescence
represents aggregated JC-1 (J-aggregates) in mitochondria and green ﬂuorescence represents nomomeric JC-1 in the cytosol. *Pb0.01, #Pb0.05. n=3 per group.
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tioxidant (Fig. 4B). Importantly, inhibition of ROS with NAC completely
prevented LA-induced increase of ERK1/2 phosphorylation (Fig. 4C).
The data suggest that LA-induced ERK1/2 activation was depended on
ROS production.
3.5. ROS inhibition abrogated LA-induced protection against DG/DO
challenge
We then examined the effects of ROS inhibition on LA-induced
protection against DG/GO challenge. The cells were pretreated with
NAC 30 min prior to LA administration. As expected, LA signiﬁcantly
prevented DG/GO-induced decrease of viability (Fig. 5A), increase of
apoptosis (Fig. 5B) and changes of morphology (Fig. 5C). Theseprotective effects of LA, however, were abrogated by NAC pretreatment.
The NAC+LA+DG/DO group showed 58.5% less viability (Fig. 5A), 9.6-
fold more condensed nuclei (Fig. 5B) and aggravated morphological
changes (Fig. 5C), respectively, compared with those of LA+DG/DO
group. NAC treatment alone had no signiﬁcant effects on cell viability,
nuclear condensation and morphology. The data suggest that ROS
induction was essential for LA-induced protection against DG/GO
challenge.
3.6. ROS induction by LA is slower and milder than that by DG/GO
Fig. 6A shows that at 30 min after treatment, ROS level was not
changed in LA group whereas signiﬁcantly increased by 29.2%
(Pb0.01) in DG/GO group, when compared with control (0 h).
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Fig. 4. ROS productionwas essential for LA-induced ERK1/2 activation. (A) Time course of
LA-induced ROS production. H9c2 cells were treated with LA for indicated times. ROS
contents were measured by DCFH-DA assay. *Pb0.01 vs. untreated control (0 h). n=3
per group. (B) The LA-induced ROS production was inhibited by NAC. H9c2 cells were
treated with NAC 30 min prior to LA administration. Twenty-four hours later, ROS
contents were measured by DCFH-DA assay. *Pb0.01, n=3–11 per group. (C) Inhibition
of ROS removed the LA-induced ERK1/2 activation. H9c2 cells were treated with NAC
30 min prior to administration with LA. Three hours after LA administration, the levels
of ERK1/2 phosphorylation were examined by Western blot analysis. *Pb0.01, n=3 per
group.
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(1 h), 17.7% (6 h) and 14.3% (24 h) in LA groups, respectively,Fig. 3. LA-induced tolerance to DG/GO challenge was mediated via ERK1/2 activation. (A) E
DG/GO for 3 h. Cell lysates were then prepared for Western blot analysis against phospho
controls. *Pb0.01, n=3 per group. (B) Effects of PD98059 on cell viability. H9c2 cells
determined by MTT assay. n=4 per group. (C) The LA-induced ERK1/2 activation was supp
of PD98059, a selective inhibitor for MEK/ERK1/2. The levels of ERK1/2 phosphorylation wer
activation abolished the protection of LA against DG/GO-induced cell death. H9c2 cells were
istration, cells were exposed to DG/GO for 24 h. Cell viability was then determined by MTT a
tion of LA against DG/GO-induced apoptosis. H9c2 cells were treated with PD98059 30 min
DG/GO for 24 h. Apoptosis was evaluated by nuclear condensation. *Pb0.01, n=4 per groucompared with time-matched DG/GO groups (Pb0.01). These results
suggest that ROS induction by LA was not only slower but also milder
compared to that by DG/GO.
We next examined the localization of ROS induced by LA or DG/GO.
As shown in Fig. 6B, the ROS induced by LA was spotted in cytosol,
which was similar with that in untreated control cells. However, the
ROS induced by DG/GO exhibited both spotted and diffused localization
within cells. The brightness of DCF ﬂuorescence in the groups was: DG/
GO>LA>Control. Furthermore, most DCF ﬂuorescence spots in con-
trols and LA group were colocalized with MitoTracker® Red CMXRos,
while lots of DCF ﬂuorescence in DG/GO group was not.
O2•− is a very important species of ROS that causes cytotoxicity. We
examined O2•− content and localization using DHE staining. As shown
in Fig. 6C, a signiﬁcant increase of O2•− level was observed in DG/GO-
treated cells when compared with untreated controls. However, the
O2•− level in LA-treated cells was comparable with that in untreated
controls. Consistently, the brightness of stained ﬂuorescence in the
groups was as follows: DG/GO>LA≈control (Fig. 6D). Both LA- and
DG/GO-induced O2•− was localized in nuclei.
3.7. ROS inhibition with NAC attenuated DG/GO-induced cell death
As shown in Fig. 7, pretreatment with NAC at concentrations of 1.5
and 5 μM signiﬁcantly attenuated the DG/GO-induced cell death by
17.9% and 44.5%, respectively, when compared with the cells treated
with DG/GO alone (Pb0.01). The DG/GO-treated cells in the presence
of 10 μM of NAC showed comparable viability with that in untreated
controls. Treatment with NAC alone did not cause changes of cell
viability.
3.8. H2O2 contents in LA-treated cells
Fig. 8A shows that after treatment with LA for 1 h, the endogenous
H2O2 levels were signiﬁcantly increased by 33.1% (4.38±0.56 nmol/
μg protein in LA group) compared with that in untreated control cells
(3.29±0.73 nmol/μg protein, Pb0.05).
We then examined the safety dosage range of exogenous H2O2 on
H9c2 cell viability. As shown in Fig. 8B, treatment with H2O2 at 5, 50
and 100 μM did not signiﬁcantly change cell viability compared with
untreated controls (0 μM group). However, the viability was decreased
when concentration of H2O2 increased tomore than 125 μM, compared
with untreated controls (Pb0.01).
4. Discussion
The signiﬁcant ﬁndings in the present study were that LA pretreat-
ment resulted in a signiﬁcant attenuation of DG/DO-induced injury in
cardiomyoblast. Moreover, LA pretreatment activated ERK1/2 signaling.
However, inhibition of ERK1/2 activation abrogated LA-induced protec-
tion against DG/GO challenge. We conﬁrmed that LA-induced ERK1/2
activationwasmediated by production of ROS,which served as a signal-
ing molecule. Inhibition of ROS by antioxidant NAC completely abol-
ished LA-induced ERK1/2 activation and cytoprotection. Our results
suggest that pretreatment with LA moderately increased ROS produc-
tion to induce a preconditioning-like effect by ERK1/2 activation there-
by increased tolerance of H9c2 cells to DG/GO challenge.RK1/2 activation following LA or DG/GO treatment. H9c2 cells were treated with LA or
r-ERK1/2 (p-ERK1/2) and total ERK1/2. The blots against α-tubulin served as loading
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treated with PD98059 30 min prior to LA administration. Twelve hours after LA admin-
ssay. *Pb0.01, n=5 per group. (E) Blockade of ERK1/2 activation removed the protec-
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*Pb0.01, n=6 per group. (B) ROS inhibition removed the protection of LA against DG/GO-induced apoptosis. H9c2 cells were pretreated with NAC for 30 min and followed by
incubation with LA for 12 h. After then, cells were stimulated with DG/GO for 24 h. Apoptosis was determined by nuclear condensation. Arrows indicate the condensed nuclei,
which is shown in bright blue. *Pb0.01, n=4–8 per group. (C) ROS inhibition abrogated the protection of LA against DG/GO-induced morphological abnormalities. H9c2 cells
were pretreated with NAC for 30 min and followed by incubation with LA for 12 h. After then, cells were stimulated with DG/GO for 24 h. Cell morphology was examined by
phase-contrast microscope at a magniﬁcation of 200×. n=3 per group.
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viability and reduced apoptosis in DG/GO-treated H9c2 cells. We
also observed that LA pretreatment prevented DG/GO-induced loss
of ΔΨm. The loss of ΔΨm is well known for increasing mitochondrial
permeability, which results in release of cytochrome C and leads to
cell apoptosis [26,27]. Therefore, LA has an anti-apoptotic property.
Indeed, we have previously reported that LA signiﬁcantly reduced
local anesthetics-induced neuron apoptosis [5]. Our results were
consistent with numerous published literatures [28,29]. For example,
Bitar et al. have shown that LA administration ameliorated apoptosis
in aortic tissues of rats with type II diabetes [28]. Kowluru has reported
that long-term administration of LA inhibited the development of
diabetic retinopathy via inhibition of capillary cell apoptosis in the ret-
ina [29]. Palacka et al. have shown that application of LA to the patients
with diabetes for 3 months signiﬁcantly improved echocardiographic
parameters [16]. Collectively, these data suggest that LA may have a
beneﬁcial effect on diabetic cardiomyopathy through anti-apoptosis.
To investigate how LA prevented DG/DO-induced apoptosis, we
examined the levels of ERK1/2 phosphorylation because it has beenwell demonstrated that activation of ERK1/2-mediated signaling
promotes cell survival and proliferation [4,30,31]. We observed that
LA signiﬁcantly increased the level of ERK1/2 phosphorylation, which
was positively correlated with LA-induced increase of viability and
decrease of apoptosis following DG/GO challenge. To determine the
role of ERK1/2 activation in LA-induced cytoprotection, we treated the
cells with PD98059 (a selective inhibitor for MEK/ERK1/2) 30 min
prior to LA administration.We observed that PD98059 completely abro-
gated the LA-induced protection against DG/DO challenge. The data
suggest that LA-induced protection against DG/GO challengewasmedi-
ated through activation of ERK1/2-dependent mechanism.
We then examined how LA activated ERK1/2 signaling pathway. It
has been shown that transient increased ROS production has been con-
sidered as a second messenger for ERK1/2 activation [4,25]. Numerous
studies have reported that LA can moderately induce intracellular ROS
production [4–7], which was positively correlated with LA-induced
improvement of cell survival [5,8,9]. Indeed, we observed that LAmod-
erately increased ROS levels in H9c2 cells, whichwas blocked by antiox-
idant NAC. More signiﬁcantly, NAC completely abrogated LA-increased
0
250
500
750
1000
1250
1500
1750
2000
0 0.5 1 6 12
Hours after treatment
R
O
S 
(ar
bit
ra
ry
 un
its
)
LA
DG/GO
*# *# *# *#
* * *
A
B
Con
LA
DG/GO
DCFH-DA MitoTracker Merge D
Con
LA
DG/GO
C
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
Con LA DG/GO
M
ea
n 
Fl
uo
re
sc
en
ce
 U
ni
ts *
*
Fig. 6. Contents and localization of ROS induced by LA or DG/GO. (A) ROS induction by LA was slower and milder than that by DG/GO. H9c2 cells were treated with LA or DG/GO for
indicated times. ROS contents were determined by DCFH-DA assay. *Pb0.01 vs. untreated control (0 h); #Pb0.01 vs. time-matched LA group. n=3 per group. (B) Localization of ROS
following LA or DG/GO administration. H9c2 cells were treated with LA or DG/GO for 1 h. Cells were stained with DCFH-DA to demonstrate ROS (green). Cells were simultaneously
stained with MitoTracker® Red CMXRos to visualize mitochondria (red). The staining was imaged using a confocal microscope. The ROS that colocalized with Mitotracker was
indicated by white arrows and that did not colocalized with Mitotracker was indicated yellow arrows. Scale bar=20 μM. n=3 per group. (C,D) DG/GO increased O2•− generation
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DG/DO- triggered cell injury. The data suggest that LA-induced toler-
ance of H9c2 cells to DG/GO challenge was mediated trough ROS-
dependent ERK1/2 activation. So far little is known about how LA
increases ROS production. However, LA has been shown to promotemi-
tochondrial permeability transition in permeabilized hepatocytes and
isolated rat liver mitochondria and increase mitochondrial respiration
in human colon cancer HT29 cells [31,32], which suggest that
mitochondria-related mechanism is quite possibly involved in the ROS
induction by LA.
Then we were interested about why LA-induced protection against
DG/GO stimulation is dependent on ROS production, because oxidative
stress iswell known to play a very important role in the cytotoxic effects
of DG/GO [17]. Glucose oxidase catalyzes the oxidation of glucose to hy-
drogen peroxide and D-glucono-δ-lactone; thus, co-administrationwithDG and GO has been used as an inductor of glucose-derived oxidative
stress in many studies [17,30,33,34,35]. Indeed, we observed a burst
of increase of ROS content in DG/GO-treated H9c2 cells and antioxidant
NAC effectively attenuatedDG/GO-inducedH9c2 cell death. LA also in-
duced ROS production; however, the induction of ROS by LA was
signiﬁcantly slower and milder compared to that by DG/GO. Further-
more, DG/GO stimulation has been shown to induce apoptosis via oxi-
dative stress [17,35]. In contrast, treatment solely with LA did not
change cell viability in current study and in previous studies [4].
When taking into account the fact that ROS could serve as a signaling
modulator [36], our data suggest that LA induced a preconditioning-
like protection against DG/GO challenge by moderately increasing ROS
production, which served as a signaling molecule to activate ERK1/2.
We observed that DG/GO activated ERK1/2 in H9c2 cells. However,
the level of ERK1/2 activation induced by DG/GO was signiﬁcantly
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Fig. 7. NAC attenuated DG/GO-induced cell death in a dose-dependent manner.H9c2 cells
were treated with NAC at indicated concentrations 30 min prior to DG/GO stimulation.
Cell viability was examined by MTT assay at 24 h after DG/GO stimulation. *Pb0.01,
n=3–6 per group.
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ROS with higher ERK1/2 activation whereas DG/GO induced higher
ROS with lower ERK1/2 activation. We observed the localization of in-
tracellular ROS induced by LA and by DG/GOwas different. Additionally,
O2•− level was signiﬁcantly increased in DG/GO-treated cells whereas
maintained normal in LA-treated cells. These results suggest that the
differential effects of LA and DG/GO on ERK1/2 activation may involve
the different localization and species of ROS they induced. It is worth-
while in future study to determine the effects of different species and
localization of ROS on ERK1/2 activation or inactivation.
In summary, this study demonstrated that pretreatment with LA
moderately increased ROS production to induce a preconditioning-
like effect by ERK1/2 activation, thereby increasing tolerance of
H9c2 cells to DG/GO challenge.
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